Capital One Financial Corp. vs Sana Biotechnology Inc — how do they compare? Capital One Financial Corp. trades at $222.47 (market cap $134.45B), while Sana Biotechnology Inc trades at $3.85 (market cap $1.13B). The key difference: Capital One Financial Corp. is far larger — about 119× Sana Biotechnology Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| COF | SANA | |
|---|---|---|
Market Cap | $134.45B | $1.13B |
Sector | Financials | Health |
52-Week High | $257.94 | $5.92 |
52-Week Low | $176.10 | $2.68 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $1.05B |
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $221.20, up 1.02% today, with a bullish technical signal from moving averages but overbought RSI readings near 77. The stock shows strong fundamentals with a P/E of 12.07 and net income margin of 16.96% for 2026, supported by robust Q2 2026 earnings beating estimates. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
Outlook is positive with a consensus price target of $251.60, implying 14% upside, driven by earnings growth and synergy capture from Discover. Key risks include integration execution, credit loss provisions, and economic sensitivity. The bullish analyst consensus (63% Buy) and institutional holdings suggest confidence in continued performance, though overbought conditions may prompt near-term volatility.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →